Rheumatoid Arthritis: key endpoint results by drug
The key endpoints of Rheumatoid Arthritis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Rheumatoid Arthritis page.
ACR20
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 67.9% | 39.7% | +28.2 | wk 24.14 · n 424 | NCT00048568 Phase 3, primary |
| Acellbia | 65.7%a | 29.4% | +36.3 | wk 24 | NCT02744196 Phase 3, primary |
| adalimumab | 63.3% | 29.5% | +33.8 | 40 mg every other week · wk 24 · n 207 | NCT00195702 Phase 3, primary |
| adalimumab-aaty (Yuflyma) | 82.7% | 82.7% (Humira) | — | wk 24 · n 324 | NCT03789292 Phase 3, primary |
| adalimumab-afzb (Abrilada) | 68.3% | 71.3% (Adalimumab-EU) | — | wk 12 · n 297 | NCT02480153 Phase 3, primary |
| adalimumab-atto (Amjevita) | 74.6% | 72.4% (Adalimumab) | — | wk 24 · n 260 | NCT01970475 Phase 3, primary |
| baricitinib | 61.7% | 39.5% | +22.2 | 4 mg · wk 12 · n 227 | NCT01721057 Phase 3, primary |
| BAT1806 | 69.9%a | 67.9% (reference tocilizumab) | — | wk 24 | NCT03830203 Phase 3, primary |
| brodalumab | 46% | 42.9% | +3.1 | 210 mg · wk 12 · n 63 | NCT00950989 Phase 2, secondary |
| certolizumab pegol | 54.8% | 23.9% | +30.9 | wk 24 · n 312 | NCT02151851 Phase 3, primary |
| etanercept | 77.5% | 56.3% (Methotrexate) | — | 25 mg · wk 24 · n 182 | NCT00445770 Phase 3, secondary |
| filgotinib | 76.6% | 49.9% | +26.7 | 200 mg · wk 12 · n 475 | NCT02889796 Phase 3, primary |
| golimumab | 44.4% | 33.1% | +11.3 | 100 mg + placebo · wk 14 · n 133 | NCT00264550 Phase 3, primary |
| HLX01 | 60.7%a | 35.9% | +24.8 | wk 24 | NCT03522415 Phase 3, primary |
| infliximab | 56.6% | 53% (Remicade-US) | — | wk 22 · n 228 | NCT02990806 Phase 3, primary |
| infliximab-dyyb (Inflectra) | 60.9%a | 58.6% (innovator infliximab (INX)) | — | wk 30 | NCT01217086 Phase 3, primary |
| infliximab-qbtx (Ixifi) | 61.1% | 63.5% (Infliximab-EU Remicade (INX)) | — | wk 14 · n 324 | NCT02222493 Phase 3, primary |
| ixekizumab | 39% | 23.4% | +15.6 | 180 mg · wk 12 · n 59 | NCT00966875 Phase 2, secondary |
| Levilimab | 68.6%a | 38.5% | +30.1 | wk 12 | NCT04227366 Phase 3, primary |
| Methotrexate | 83.2% | 50% (DMARD + Methotrexate) | — | wk 24 · n 279 | NCT00848354 Phase 4, secondary |
| obefazimod | 15.8% | 20% | −4.2 | 100 mg · wk 12 · n 19 | NCT03813199 Phase 2, secondary |
| PF-05280586 | 77.1% | 90% (Rituximab-EU) | — | wk 25 · n 58 | NCT01643928 Phase na, primary |
| Piclidenoson | 42.9% | 21.6% | +21.3 | 1 mg · wk 12 · n 42 | NCT01034306 Phase 2, primary |
| Rituximab | 50.6% | 23.3% | +27.3 | 2 x 1.0 g · wk 24 · n 170 | NCT00299130 Phase 3, primary |
| Sarilumab | 66.4% | 33.4% | +33 | 200 mg q2w · wk 24 · n 399 | NCT01061736 Phase 2/3, primary |
| tocilizumab | 60.9% | 31.5% | +29.4 | 162 mg sc · wk 24 · n 437 | NCT01232569 Phase 3, primary |
| tofacitinib | 52.7% | 31.2% | +21.5 | 5 mg · wk 24 · n 311 | NCT00856544 Phase 3, primary |
| upadacitinib | 63.8% | 35.7% | +28.1 | 15 mg · wk 12 · n 221 | NCT02675426 Phase 3, primary |
Drugs checked with no result here: 50 not reported, 6 not posted, 2 trial running.
ACR50
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 39.9% | 16.8% | +23.1 | wk 24.14 · n 424 | NCT00048568 Phase 3, secondary |
| adalimumab | 41.2% | 45.9% (Methotrexate) | — | wk 52 · n 274 | NCT00195663 Phase 3, primary |
| adalimumab-afzb (Abrilada) | 59.6% | 54.7% (Adalimumab-EU) | — | wk 26 · n 297 | NCT02480153 Phase 3, secondary |
| adalimumab-atto (Amjevita) | 49.2% | 52% (Adalimumab) | — | wk 24 · n 244 | NCT01970475 Phase 3, secondary |
| baricitinib | 44.1% | 21.5% | +22.6 | 4 mg · wk 24 · n 227 | NCT01721057 Phase 3, secondary |
| brodalumab | 9.5% | 12.7% | −3.2 | 210 mg · wk 12 · n 63 | NCT00950989 Phase 2, primary |
| certolizumab pegol | 36.5% | 7.1% | +29.4 | wk 24 · n 312 | NCT02151851 Phase 3, secondary |
| etanercept | 54.4% | 32.4% (Methotrexate) | — | 25 mg · wk 24 · n 182 | NCT00445770 Phase 3, secondary |
| filgotinib | 57.9% | 33.3% | +24.6 | 200 mg · wk 24 · n 475 | NCT02889796 Phase 3, secondary |
| golimumab | 32.7% | 29.4% | +3.3 | 100 mg + placebo · wk 24 · n 159 | NCT00264537 Phase 3, primary |
| infliximab | 27.8% | 25.6% (Remicade-US) | — | wk 22 · n 227 | NCT02990806 Phase 3, secondary |
| Methotrexate | 62.0% | 23.2% (DMARD + Methotrexate) | — | wk 24 · n 279 | NCT00848354 Phase 4, primary |
| PF-05280586 | 51.4% | 30% (Rituximab-EU) | — | wk 25 · n 58 | NCT01643928 Phase na, primary |
| Piclidenoson | 18.9% | 9.4% | +9.5 | 1 mg · wk 12 · n 37 | NCT01034306 Phase 2, secondary |
| Rituximab | 25.9% | 9.3% | +16.6 | 2 x 1.0 g · wk 24 · n 170 | NCT00299130 Phase 3, secondary |
| Sarilumab | 40.8% | 18.2% | +22.6 | 200 mg q2w · wk 24 · n 184 | NCT01709578 Phase 3, secondary |
| tocilizumab | 32.2% | 9.7% | +22.5 | 8 mg/kg · wk 24 · n 398 | NCT00106535 Phase 3, secondary |
| tofacitinib | 33.8% | 12.7% | +21 | 5 mg · wk 26 · n 311 | NCT00856544 Phase 3, secondary |
| upadacitinib | 52.1% | 28.3% (Methotrexate) | — | 15 mg · wk 12 · n 317 | NCT02706873 Phase 3, primary |
Drugs checked with no result here: 54 not reported, 11 not posted, 2 trial running.
ACR70
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 19.8% | 6.5% | +13.3 | wk 24.14 · n 424 | NCT00048568 Phase 3, secondary |
| adalimumab | 47.4% | 22.7% | +24.7 | wk 26 · n 171 | NCT00870467 Phase 3, secondary |
| adalimumab-afzb (Abrilada) | 29.6% | 31% (Adalimumab-EU) | — | wk 26 · n 297 | NCT02480153 Phase 3, secondary |
| adalimumab-atto (Amjevita) | 26% | 22.9% (Adalimumab) | — | wk 24 · n 246 | NCT01970475 Phase 3, secondary |
| baricitinib | 24.2% | 7.9% | +16.3 | 4 mg · wk 24 · n 227 | NCT01721057 Phase 3, secondary |
| brodalumab | 0% | 3.2% | −3.2 | 210 mg · wk 12 · n 63 | NCT00950989 Phase 2, secondary |
| certolizumab pegol | 16.7% | 2.7% | +14 | wk 24 · n 312 | NCT02151851 Phase 3, secondary |
| etanercept | 25.8% | 11.9% (Methotrexate) | — | 25 mg · wk 24 · n 182 | NCT00445770 Phase 3, secondary |
| filgotinib | 36.2% | 14.9% | +21.3 | 200 mg · wk 24 · n 475 | NCT02889796 Phase 3, secondary |
| golimumab | 16.1% | 25.9% (Golimumab) | — | 100 mg · wk 24.14 · n 70 | NCT01715896 Phase 2, primary |
| infliximab | 10.6% | 12.1% (Remicade-US) | — | wk 22 · n 227 | NCT02990806 Phase 3, secondary |
| Methotrexate | 34.8% | 11.3% (DMARD + Methotrexate) | — | wk 24 · n 279 | NCT00848354 Phase 4, secondary |
| PF-05280586 | 22.9% | 10% (Rituximab-EU) | — | wk 25 · n 58 | NCT01643928 Phase na, primary |
| Piclidenoson | 10.8% | 3.1% | +7.7 | 1 mg · wk 12 · n 37 | NCT01034306 Phase 2, secondary |
| Rituximab | 10% | 5.2% | +4.8 | 2 x 1.0 g · wk 24 · n 170 | NCT00299130 Phase 3, secondary |
| Sarilumab | 16.3% | 7.2% | +9.1 | 200 mg q2w · wk 24 · n 184 | NCT01709578 Phase 3, secondary |
| tocilizumab | 12.6% | 2% | +10.6 | 8 mg/kg · wk 24 · n 398 | NCT00106535 Phase 3, secondary |
| tofacitinib | 25.4% | 12.1% (MTX) | — | 5 mg BID · wk 24 · n 366 | NCT01039688 Phase 3, primary |
| upadacitinib | 20.8% | 5.9% | +14.9 | 15 mg · wk 12 · n 221 | NCT02675426 Phase 3, secondary |
Drugs checked with no result here: 54 not reported, 11 not posted, 2 trial running.
DAS28-CRP remission
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 41.4% | 23.3% | +18.1 | wk 52 · n 256 | NCT00122382 Phase 3, primary |
| adalimumab | 35.9% | 11.4% (Standard of Care) | — | wk 26 · n 39 | NCT01162421 Phase 4, secondary |
| certolizumab pegol | 16% | 5.7% | +10.3 | wk 12 · n 851 | NCT00717236 Phase 3, secondary |
| etanercept | 58.2% | 43.6% (Standard COBRA-Slim Induction) | — | wk 28 · n 55 | NCT03649061 Phase 4, secondary |
| filgotinib | 48.4% | 16.2% | +32.2 | 200 mg · wk 24 · n 475 | NCT02889796 Phase 3, secondary |
| PF-05280586 | 45.7% | 20% (Rituximab-EU) | — | wk 25 · n 58 | NCT01643928 Phase na, primary |
| Sarilumab | 28.8% | 7.2% | +21.6 | 200 mg q2w · wk 24 · n 184 | NCT01709578 Phase 3, secondary |
| tofacitinib | 23.0% | 5.2% | +17.8 | 5 mg · wk 26 · n 309 | NCT00847613 Phase 3, secondary |
| upadacitinib | 48.3% | 18.5% (Methotrexate) | — | 15 mg · wk 24 · n 317 | NCT02706873 Phase 3, primary |
Drugs checked with no result here: 58 not reported, 15 not posted, 4 trial running.
HAQ-DI, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | -0.7 | -0.7 (Abatacept) | — | 125 mg SC · wk 76 · n 52 | NCT01001832 Phase 2/3, primary |
| adalimumab | -0.6 | -0.3 | −0.3 | 40 mg every other week · wk 52 · n 204 | NCT00195702 Phase 3, primary |
| adalimumab-afzb (Abrilada) | -0.7 | -0.7 (Adalimumab-EU) | — | wk 26 · n 297 | NCT02480153 Phase 3, secondary |
| baricitinib | -0.5 | -0.3 | −0.2 | 4 mg · wk 12 · n 227 | NCT01721057 Phase 3, secondary |
| certolizumab pegol | -0.5 | -0.2 | −0.3 | wk 24 · n 306 | NCT02151851 Phase 3, secondary |
| etanercept | -0.6 | -0.3 (Methotrexate) | — | 25 mg · wk 24 · n 182 | NCT00445770 Phase 3, secondary |
| filgotinib | -0.8 | -0.6 | −0.2 | 200 mg · wk 24 · n 475 | NCT02889796 Phase 3, secondary |
| golimumab | 0.1 | 0.1 | ±0 | 100 mg + placebo · wk 24 · n 133 | NCT00264550 Phase 3, primary |
| infliximab | -0.3 | -0.4 (Remicade-US) | — | wk 22 · n 227 | NCT02990806 Phase 3, secondary |
| ixekizumab | -0.5 | -0.2 | −0.3 | 180 mg · wk 12 · n 37 | NCT00966875 Phase 2, secondary |
| Methotrexate | -0.8 | -0.5 (DMARD + Methotrexate) | — | wk 24 · n 279 | NCT00848354 Phase 4, secondary |
| obefazimod | -0.1 | -0.2 | +0.1 | 100 mg · wk 12 · n 19 | NCT03813199 Phase 2, secondary |
| PF-05280586 | -0.4 | -0.5 (Rituximab) | — | wk 25 · n 73 | NCT01526057 Phase 2, secondary |
| Rituximab | -1.0 | -0.8 | −0.2 | 1.0 g x 2 · wk 52 · n 249 | NCT00299104 Phase 3, secondary |
| Sarilumab | -0.5 | -0.3 | −0.2 | 200 mg q2w · wk 12 · n 171 | NCT01709578 Phase 3, primary |
| tocilizumab | -0.5 | -0.3 | −0.2 | 162 mg sc · wk 24 · n 348 | NCT01232569 Phase 3, secondary |
| tofacitinib | -0.5 | -0.2 | −0.3 | 5 mg · wk 13 · n 240 | NCT00814307 Phase 3, primary |
| upadacitinib | -0.6 | -0.3 | −0.3 | 15 mg · wk 12 · n 216 | NCT02675426 Phase 3, secondary |
Drugs checked with no result here: 55 not reported, 11 not posted, 2 trial running.
Modified Sharp score, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 0.5 | 2.5 | −2 | wk 52 · n 401 | NCT02504268 Phase 3, secondary |
| adalimumab | 0.1 | 2.7 | −2.6 | 40 mg every other week · wk 52 · n 183 | NCT00195702 Phase 3, primary |
| baricitinib | 0.3 | 0.8 | −0.5 | wk 24 · n 470 | NCT01710358 Phase 3, secondary |
| certolizumab pegol | 0.4 | 1.6 | −1.2 | wk 52 · n 158 | NCT01451203 Phase 3, primary |
| Denosumab (Prolia) | 0 | 0 | ±0 | 180 mg · wk 24 · n 69 | NCT00095498 Phase 2, secondary |
| etanercept | 3.3 | 9.8 (Methotrexate) | — | 25 mg · wk 52 · n 181 | NCT00445770 Phase 3, primary |
| filgotinib | 0.1 | 0.4 | −0.2 | 200 mg · wk 24 · n 467 | NCT02889796 Phase 3, secondary |
| golimumab | 1.3 | 1.4 | −0.1 | 100 mg + placebo · wk 52 · n 159 | NCT00264537 Phase 3, primary |
| Methotrexate | 0.4 | 1.4 (DMARD + Methotrexate) | — | wk 24 · n 247 | NCT00848354 Phase 4, secondary |
| Rituximab | 0.4 | 1.1 | −0.7 | 1.0 g x 2 · wk 52 · n 244 | NCT00299104 Phase 3, primary |
| tocilizumab | 0.3 | 1.1 | −0.8 | 8 mg/kg · wk 52 · n 348 | NCT00106535 Phase 3, primary |
| tofacitinib | 0.1 | 0.5 | −0.3 | 5 mg · wk 26 · n 286 | NCT00847613 Phase 3, primary |
| upadacitinib | 0.1 | 0.7 (Methotrexate) | — | 15 mg · wk 24 · n 279 | NCT02706873 Phase 3, primary |
Drugs checked with no result here: 58 not reported, 12 not posted, 3 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 86 approved or late-stage drugs with a featured trial in Rheumatoid Arthritis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.